Annovis Bio has announced significant progress in its clinical development of buntanetap, an investigational therapy for neurodegenerative diseases, with the launch of a pivotal Phase 3 trial targeting early Alzheimer’s disease. As of March 2026, approximately 65% of the required participants have been enrolled across 83 clinical sites in the U.S., aiming to assess both symptomatic effects and potential disease-modifying outcomes over an 18-month period.

This development is crucial for the longevity and healthspan field, as it not only represents a potential breakthrough in Alzheimer’s treatment but also builds on earlier biomarker findings that indicate reductions in neurodegeneration and toxic protein accumulation. The ongoing trial’s safety review has already led to a recommendation for continuation without modifications, underscoring the therapy’s promise.

For professionals in aging biology and therapeutics, Annovis’s focus on multiple pathological pathways in neurodegeneration could reshape treatment paradigms. I encourage you to explore the full details of this promising development in the original article.

Source: longevity.technology